PMCB icon

PharmaCyte Biotech
PMCB

Overview Fund Activity

28 hedge funds and large institutions have $2.02M invested in PharmaCyte Biotech in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
28
Holders Change
-1
Holders Change %
-3.45%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
TSS
1
Two Sigma Securities
New York
$54.4K
2
UBS Group
2
UBS Group
Switzerland
$54K
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$377K
4
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$107K
5
Renaissance Technologies
5
Renaissance Technologies
New York
$95.1K

Top Sellers

1
Geode Capital Management
1
Geode Capital Management
Massachusetts
$346K
2
Citadel Advisors
2
Citadel Advisors
Florida
$0
3
BlackRock
3
BlackRock
New York
$26.2K
4
Osaic Holdings
4
Osaic Holdings
Arizona
$1K
5
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$5K
Name Holding Trade Value Shares
Change 		Shares
Change %
Citadel Advisors
26
Citadel Advisors
Florida
– -$20.3K -8,561 Closed
Wells Fargo
27
Wells Fargo
California
– -$130 -55 Closed
PWMG
28
Private Wealth Management Group
New Jersey
– -$100 -42 Closed
1
2